Health Law Update

Home | Health Law Update

On Jan. 23, the Food and Drug Administration (FDA) finalized industry guidance for clinical research using cannabis and cannabis-derived compounds, <a href="https://www.fda.gov/media/164690/download"><em>Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research</em></a>. The need for the guidance stemmed from the 2018 Farm Bill, which legalized the production and sale of hemp (cannabis below 0.3 percent delta-9 THC by dry weight) and removed it from the Schedule I&nbsp;substance list.

core/paragraph

Read <a href="https://www.bakerlaw.com/alerts/fda-issues-guidance-on-clinical-research-with-cannabis" target="_blank" rel="noreferrer noopener">full alert.</a>

Washington, D.C.

Partner

Winston S. Kirton

Associate

Laura E. Macherelli

Randal M. Shaheen

Lee H. Rosebush

FDA Issues Guidance on Clinical Research with Cannabis